(Q30446429)

21 June 2017

1 reference

title

Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis (English)

1 reference

21 June 2017

0 references

1 reference

Behfar Ehdaie

1

1 reference

PubMed ID

18588455

21 June 2017

Dan Theodorescu

series ordinal

2

1 reference

21 June 2017

1 July 2008

1 reference

Expert Review of Anticancer Therapy

21 June 2017

1 reference

21 June 2017

8

1 reference

21 June 2017

1103-1110

1 reference

21 June 2017

7

1 reference

21 June 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Mechanisms of disease: The epidemiology of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Management of stage T1 tumors of the bladder: International Consensus Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Prognostic factors in local surgical treatment of invasive bladder cancer, with special reference to the presence of urothelial dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Fibroblast growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

p53: traffic cop at the crossroads of DNA repair and recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

The E2F transcription factor is a cellular target for the RB protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Molecular biology of bladder cancer: prognostic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Apoptosis and chemotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Steps in tumor metastasis: new concepts from intravital videomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Gene expression profiling of noninvasive primary urothelial tumours using microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Mass spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1103

10.1586/14737140.8.7.1103

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

18588455